Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07506109

A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer

Colorectal cancer (CRC) is the second leading cause of cancer-related death globally. BRAF V600E mutations occur in approximately 12% of metastatic CRC (mCRC) patients, conferring an extremely poor prognosis with a median overall survival (OS) of only 11 months for standard chemotherapy. Most BRAF V600E-mutant mCRC are microsatellite stable (MSS) and do not benefit from single-agent PD-1/PD-L1 inhibition.

Preclinical and clinical evidence indicates that BRAF inhibition in combination with EGFR blockade can induce DNA damage, trigger a deficient mismatch repair (dMMR) phenotype, and increase tumor mutational burden (TMB), thereby sensitizing MSS tumors to immune checkpoint inhibition. This provides a strong rationale for combining BRAF/EGFR inhibitors with anti-PD-1 and anti-CTLA-4 immunotherapy.

This is a single-arm, open-label, Phase II clinical trial. The primary objective is to evaluate the efficacy and safety of the triplet combination of sintilimab (anti-PD-1), ipilimumab N01 (anti-CTLA-4), cetuximab (anti-EGFR), and dabrafenib (BRAF inhibitor) in patients with MSS, BRAF V600E-mutant mCRC.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

BRAF V600E Brain Diseases Central Nervous System Diseases Cerebellar Diseases Cetuximab Colonic Diseases Colorectal Cancer Colorectal Neoplasms Congenital, Hereditary, and Neonatal Diseases and Abnormalities Dabrafenib Digestive System Diseases Digestive System Neoplasms Gastrointestinal Diseases Gastrointestinal Neoplasms Genetic Diseases, Inborn Heredodegenerative Disorders, Nervous System Intestinal Diseases Intestinal Neoplasms Ipilimumab N01 MSS (Microsatellite Stable) Neoplasms Neoplasms by Site Nervous System Diseases Neurodegenerative Diseases Rectal Diseases Sintilimab Spinal Cord Diseases Spinocerebellar Degenerations

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Peking union medical college hospital, Beijing, Beijing Municipality, China

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Provided written informed consent.
  • Age ≥ 18 years.
  • Histologically or pathologically confirmed colorectal adenocarcinoma.
  • Documented microsatellite stable (MSS) and BRAF V600E mutation by prior genomic testing.
  • Locally advanced unresectable disease or distant metastasis.
  • No prior treatment with BRAF/MEK/ERK inhibitors, EGFR inhibitors, or immune checkpoint inhibitors (ICI).
  • Presence of measurable target lesions per RECIST 1.1.
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1.
  • Adequate organ function, based on the following laboratory values obtained within 7 days prior to Cycle 1 Day 1:
  • Hemoglobin ≥ 9.0 g/dL.
  • Absolute neutrophil count ≥ 1,500/mm³ (≥ 1.5 × 109/L).
  • Platelet count ≥ 80,000/mm³ (≥ 80 × 109/L).
  • Serum total bilirubin ≤ 1.5 × upper limit of normal (ULN).
  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × ULN.
  • Serum creatinine ≤ 1.5 × ULN or creatinine clearance ≥ 50 mL/min.
  • Willing and able to comply with study procedures and visit schedule.

Exclusion criteria

  • Received any approved or investigational systemic anti-tumor therapy within 4 weeks prior to enrollment.
  • Underwent any surgery or invasive procedure within 4 weeks prior to study initiation (exceptions include venous catheter placement and paracentesis/drainage).
  • Multiple primary malignancies (exceptions include completely resected basal cell carcinoma, stage I squamous cell carcinoma, carcinoma in situ, intramucosal carcinoma, superficial bladder cancer, or any other cancer that has been in complete remission for at least 3 years).
  • Presence of severe comorbidities or serious medical conditions.
  • Pregnant or breastfeeding females.
  • The investigator deems the patient unsuitable for participation in this study.

Treatment and study plan

Ipilimumab N01

Drug

1mg/kg ivd，q6w or 3mg/kg ivd，q12w followed by maintenance therapy with Ipilimumab N01 1 mg/kg ivd, q6w. The specific dosage and administration schedule should be referred to the relevant study design.

Other names: IBI-310

Sintilimab

Drug

2mg/kg ivd, q3w

Other names: IBI-308

Cetuximab

Drug

500mg/m2 ivd，q2w

Dabrafenib

Drug

150mg po bid

Primary outcomes

  1. Progression-Free Survival (PFS)

    Time frame: up to 2 years

    PFS is defined as the time from study entry until the first occurrence of disease progression or death from any cause, whichever comes first. If a subject does not experience disease progression during the trial, PFS is defined as the date of the last confirmed progression-free survival assessment for that subject.

Secondary outcomes

  1. Disease Control Rate (DCR)

    Time frame: up to 1 year

    DCR: The percentage of patients with a best overall response of Complete Response (CR), Partial Response (PR), or Stable Disease (SD) that is maintained for at least 4 weeks, among all patients evaluable for efficacy.

  2. Objective Response Rate (ORR)

    Time frame: up to 1 year

    ORR: The proportion of patients who achieve a reduction in tumor size of a predefined magnitude that is maintained for a specified duration, including cases of CR and PR.

    Tumor objective response will be assessed in accordance with the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. All subjects must have measurable tumor lesions at baseline. Efficacy assessments will be categorized as Complete Response (CR), Partial Response (PR), Stable Disease (SD), or Progressive Disease (PD) based on RECIST v1.1 criteria.

  3. Overall Survival (OS)

    Time frame: up to 3 years

    OS is defined as the time from study entry to death from any cause. For subjects who are still alive at the final follow-up, OS will be censored at the time of the final follow-up. For lost-to-follow-up subjects, OS will be censored at the time of the last confirmed alive assessment prior to loss to follow-up. OS for censored subjects is defined as the time from study entry to the censoring date.

  4. Treatment-Related Adverse Events (TRAE)

    Time frame: up to 3 years

    Treatment-Related Adverse Events (TRAE) as assessed by CTCAE v5.0, including serious adverse events (SAEs)

Sponsors and collaborators

Lead sponsor

Tianjin Medical University Cancer Institute and Hospital

Other

Registry information

Important dates

Study start
2026
Primary completion
2027
Study completion
2028
First posted
Apr 1, 2026
Registry last updated
Apr 7, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.